KHOS-240S

KHOS-240S is an osteosarcoma cell line that is derived from human bone sarcoma tissue. This cell line, along with its variants, has been extensively used in research focused on osteosarcoma, a primary malignant bone tumor that predominantly affects children and young adults. Osteosarcoma is characterized by the production of immature bone (osteoid) by malignant cells and is notorious for its aggressive behavior and potential for early metastasis, particularly to the lungs.

The KHOS-240S cell line is resistant to several kinase inhibitors, including those targeting the PI3K-Akt-mTOR pathway. This resistance to common therapeutic targets makes KHOS-240S particularly valuable for studying the mechanisms of drug resistance in osteosarcoma and exploring alternative therapeutic strategies. Researchers have used this cell line to screen a variety of oncology drugs and investigational agents, which has led to the identification of compounds that could potentially overcome resistance mechanisms. The expression profile of genes associated with drug resistance and osteosarcoma biology, such as those involved in the mTOR signaling pathway, is of particular interest in studies utilizing KHOS-240S.

Moreover, KHOS-240S has been utilized in the exploration of microRNA expression patterns, which may correlate with drug sensitivity or resistance. This cell line’s specific resistance to PI3K-Akt-mTOR pathway inhibitors provides an essential model for understanding how osteosarcomas may evade targeted therapies and offers a basis for the development of novel therapeutic approaches that could enhance treatment efficacy in resistant osteosarcoma subtypes.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.